Five branded products, four tumor types, and a regulatory arc that walked back late-line ovarian approvals even as AKEEGA just reached hormone-sensitive prostate cancer.

Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a phase I clinical trial—causes DNA damage in cancer cells which is ...

As treatment sequencing in ovarian cancer (OC) continues to evolve, an increasing proportion of patients acquire platinum-resistance following frontline poly(ADP-ribose) polymerase (PARP) inhibitor ...

PARP inhibitors (PARPi) leverage synthetic lethality in BRCA-deficient cancers, yet intrinsic resistance limits therapeutic benefit. Through functional proteomics, this study uncovers that PARPi ...

Prostate cancer is the second most common cancer in men worldwide, with nearly 1.4 million new cases diagnosed each year. PARP inhibitors have transformed the treatment landscape for ...

Researchers at the University of Colorado (UC) Denver, Anschutz Medical Campus, have discovered a novel combination treatment strategy that could offer new hope to ovarian cancer patients who stop ...

One key limitation of the ARPI and PARP inhibitor combination studies is that few patients had received an ARPI in the castration-sensitive state, the current standard of care, and it is therefore ...

Please provide your email address to receive an email when new articles are posted on . Nearly half of men with metastatic castration-resistant prostate cancer eligible for PARP inhibitors do not get ...